You are here

Developing and Testing the Opioid Rapid Response System

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41DA053078-01
Agency Tracking Number: R41DA053078
Amount: $307,773.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIDA
Solicitation Number: PA19-029
Timeline
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-09-30
Award End Date (Contract End Date): 2021-06-30
Small Business Information
765 LONG HILL RD
Gillette, NJ 07933-1321
United States
DUNS: 078820648
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MICHAEL HECHT
 (814) 360-1893
 hechtpsu@gmail.com
Business Contact
 MICHAEL HECHT
Phone: (814) 360-1893
Email: hechtpsu@gmail.com
Research Institution
 INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
 
980 INDIANA AVENUE
INDIANAPOLIS, IN 46202-2915
United States

 Nonprofit College or University
Abstract

The goal of this project is to prevent deaths from opioid overdoses through developing and
commercializing the Opioid Rapid Response System (ORRS). This system is designed to reduce the cost
of the opioid epidemic by developing standardized and effective procedures for recruiting and training
citizen responders to use the PulsePoint app to administer life-saving naloxone/Narcan. This i-Corps
supplement will assess the commercialization potential for ORRS and develop a plan for dissemination.The Opioid Rapid Response System (ORRS) is designed to reduce the cost in lives of the opioid epidemic
by developing a standardized and effective methods for recruiting and training citizen responders to use
the PulsePoint app to administer lifesaving naloxone/Narcan. This app is currently used in 4,000
communities to link 911 calls for cardiac arrest incidents to responders trained in CPR. The current
project will extend the application of the PulsePoint app to opioid overdose events by developing a
system for recruiting and training citizen responders to react to opioid overdose events. This is vital
since overdose events must be responded to within a very narrow timeframe estimated to be 30
minutes or less. Since formal or professional responders like EMS, fire and police services may have
trouble meeting this restriction due to geographic distance or density, it is desirable to put
naloxone/Narcan in the hands of trained citizen responders. Even in the absence of training, research
demonstrates the lay persons can provide this life saving service. In addition, previous research suggests
that existing training does not demonstrate efficacy and is not widely available. A pilot project found
that this training does not instill the confidence needed in a lifesaving situation, even among
professionals. However, merely developing an evidence-based system provides no assurances that it will
be used. Implementation science research has repeatedly demonstrated that even effective
interventions may not be successfully commercialized. Therefore, the goal of the i-Corp supplement is to
provide additional training in the commercialization process, conduct approximately 100 interviews with
end users (i.e., state and county health departments) and develop a more advanced commercialization
plan. The interviews will identify the point-of-sale and point-of-contact decisions makers for users of the
PulsePoint app as well as comparable decision makers in communities that do not use the app. They will
describe the decision processes as well as other adoption factors. At the conclusion of the project a
report will be written demonstrating the commercialization potential of the ORRS.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government